Company / Operating Cash Flow
Cartesian Therapeutics, Inc. Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$23.7M
FY2025
5-year range
-$60.4M / $34.9M
FY2021-FY2025
Trend
+53.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 8 years, ranging from -$60M in FY2023 to $35M in FY2022.
Based on SEC 10-K filings.
-$24M in FY2025.
Improved from -$60M to -$24M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow increased 53.7% year-over-year.
- Peak operating cash flow was recorded in FY2022.
- Lowest operating cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -0.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$23.7M | +53.7% |
| FY2024 | -$51.2M | +15.3% |
| FY2023 | -$60.4M | -273.1% |
| FY2022 | $34.9M | +167.8% |
| FY2021 | -$51.4M | +13.1% |
| FY2020 | -$59.2M | -13.7% |
| FY2019 | -$52.0M | -310.1% |
| FY2016 | -$12.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026